Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Why some dogs do not respond to epilepsy treatments
border collie
Past research has shown around a third of dogs do not respond to anti-epilepsy drugs.
Breed and sex impact the effectiveness of AEDs, says RVC

New research has shed light on why around a third of dogs do not respond to epilepsy treatments.

Sex, breed and frequency of seizures all affect the likelihood of achieving remission, according to specialists from the Royal Veterinary College (RVC).

Epilepsy affects around 50,000 dogs and 600,000 people in the UK, making it the most common chronic neurological condition found in both dogs and humans. Research has shown anti-epilepsy drugs (AEDs) fail to reduce seizures by 50 per cent in a third of cases.

RVC researchers sought to find out why, using patient data from six years of medical history, taken from the college's small animal referral hospital.

Just 14 per cent of the dogs studied were in seizure-free remission at the point of follow up.

The findings, which will be published in the academic journal PLOS ONE, show that male dogs were less likely than female dogs to become seizure-free while receiving AED treatment.

Border collies and German shepherds were also found to be significantly less likely to respond to treatment. Past studies have looked at the impact of AEDs on different dog types, but the RVC was able to explore how this affects a wider variety of breeds.

Researchers say they also discovered that the likelihood of achieving remission is not affected by the number of seizures experienced before treatment begins. Traditionally in human medicine, treatment is given immediately after the onset of epilepsy.

Rowena Packer, co-author of the study and clinical investigations research assistant at the RVC, said managing owners' expectations of drug treatments for epilepsy is important.

"In its worst form canine epilepsy can be life threatening to dogs, but it is a dog's long-term quality of life that is most affected. It can also take a toll on the owners who have to manage this unpredictable, uncontrollable condition."

Lead author Professor Holger Volk, specialist in neurology and neurosurgery and clinical director of the RVC's small animal referral clinic, added: "Drug treatments can be successful in reducing seizures, but it is important to note that consistent remission is difficult to attain."

Researchers say further study of AED treatment in dogs could even improve understanding of epilepsy in humans.

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.